California Public Employees Retirement System lifted its stake in AnaptysBio Inc (NASDAQ:ANAB) by 26.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 25,200 shares of the biotechnology company’s stock after acquiring an additional 5,282 shares during the quarter. California Public Employees Retirement System owned 0.09% of AnaptysBio worth $1,608,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. TIAA CREF Investment Management LLC lifted its holdings in shares of AnaptysBio by 18.8% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 48,514 shares of the biotechnology company’s stock worth $4,840,000 after acquiring an additional 7,670 shares during the last quarter. MetLife Investment Advisors LLC lifted its holdings in shares of AnaptysBio by 55.0% in the 3rd quarter. MetLife Investment Advisors LLC now owns 12,774 shares of the biotechnology company’s stock worth $1,274,000 after acquiring an additional 4,535 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of AnaptysBio by 20.0% in the 3rd quarter. Vanguard Group Inc now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after acquiring an additional 308,517 shares during the last quarter. FMR LLC lifted its holdings in shares of AnaptysBio by 11.7% in the 3rd quarter. FMR LLC now owns 3,935,467 shares of the biotechnology company’s stock worth $392,642,000 after acquiring an additional 410,918 shares during the last quarter. Finally, Man Group plc acquired a new position in shares of AnaptysBio in the 3rd quarter worth approximately $536,000.
AnaptysBio stock traded up $0.54 during mid-day trading on Friday, reaching $74.00. 178,180 shares of the company’s stock were exchanged, compared to its average volume of 222,857. AnaptysBio Inc has a twelve month low of $54.26 and a twelve month high of $110.00. The firm has a market cap of $2.00 billion, a PE ratio of -29.60 and a beta of 2.29.
Several brokerages have recently commented on ANAB. Cantor Fitzgerald restated a “buy” rating and issued a $140.00 price objective on shares of AnaptysBio in a report on Tuesday, March 26th. Stifel Nicolaus set a $124.00 target price on shares of AnaptysBio and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Guggenheim assumed coverage on shares of AnaptysBio in a report on Friday, February 22nd. They set a “buy” rating and a $135.00 target price on the stock. Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a report on Friday, March 1st. Finally, Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. AnaptysBio has a consensus rating of “Buy” and a consensus price target of $123.42.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Article: What is a Backdoor Roth IRA?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.